p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer

International Journal of Biological Markers

Volumn 21, Issue 2, 2006, Pages 81-87

  Fijołek, Justyna ^a   Wiatr, E ^a   Rowinska Zakrzewska E ^a   Giedronowicz, D ^a   Langfort, R ^a   Chabowski, M ^a   Orlowski T ^a   Roszkowski, K ^a  

^a NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Chemotherapy response; HER2 neu; Non small cell lung cancer; p53

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PARAFFIN; PROTEIN ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CLINICAL PROTOCOL; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLAND; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 33747045772     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.838     Document Type: Article

References (41)

1. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479-85.
2. Waller DA. Neoadjuvant chemotherapy in non-small cell lung cancer - the UK experience. Lung Cancer 2001; 34: 31-3.
3. Tsai C-M, Chang KT, Perng R-P, et al. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 1993; 85: 897-901.
4. Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996; 32A: 921-6.
5. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-9.
6. Ferreira CG, Tolls C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999; 10: 1011-21.
7. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong K-M. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 2000; 161: 1355-67.
8. O'Connor PM, Jackman J, Bae I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300.
9. Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001; 92: 386-94.
10. Lowe SW, Bodis S, McClatchey A, et al. p53 status and efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
11. Tsai CM, Chang KT, Wu LH, et al. Correlation between intrinsic chemoresistance and HER-2/neu gene expression, p53 mutations and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996; 56: 206-9.
12. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999; 18: 477-85.
13. Hung M-C, Lau Y-K. Basic science of HER-2/neu: a review. Semin Oncol 1999; 26 (suppl 12): 51-9.
14. neu. Cancer Res 1996; 56: 794-801.
15. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000; 6: 4932-8.
16. Booton R, Ward T, Heighway J, Thatcher N. A pharmacogenomic approach to improving outcome of chemotherapy for advanced non-small cell lung cancer (NSCLC). Int J Biol Markers 2004; 19: 13 (abstract).
17. Hirsch FR, Franklin WA, Veve R, Varella-Garcia M, Bunn PA. HER2/neu expression in malignant lung tumors. Semin Oncol 2002; 29 (suppl 4): 51-8.
18. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles or the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005; 11: 232-41.
19. Selvaggi G, Scagliotti GV, Torri V, et al. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Cancer 2002; 94: 2669-74.
20. Graziano SL, Tatum A, Herndon JE II, et al. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B Study. Lung Cancer 2001; 33: 115-23.
21. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004; 10; 136-43.
22. Kim Y-C, Park K-O, Kern J-A, et al. The interactive effect of Ras, HER2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 1998; 22: 181-90.
23. Junker K, Stachetzki U, Rademacher D, et al. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer 2005; 48: 59-67.
24. Rusch V, Klimstra D, Venkatraman E, et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995; 55: 5038-42.
25. Fujino M, Dosaka-Akita H, Harada M, et al. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer. Cancer 1995; 76: 2457-63.
26. Reinmuth N, Brandt B, Kunze W-P, et al. Ploidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000; 16: 991-6.
27. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6: 4055-63.
28. Gregorc V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2003, 39, 41-8.
29. Tanaka F, Otake Y, Yanagihara K, et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 2001; 84: 263-9.
30. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001; 18: 705-19.
31. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HFR-2 overexpression with prognosis in non small cell lung carcinoma: a metaanalysis. Cancer 2005; 103: 1865-73.
32. Meert AP, Martin B, Paesmans M, et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003; 89, 959-65.
33. Kawasaki M, Nakanishi Y, Kuwano K, et al. The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer. Clin Cancer Res 1997; 3: 1195-200.
34. Kandioler-Eckersberger D, Kappel S, Mittlbock M, et al. The p53 genotype but not immunohistochemical results is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117: 744-50.
35. Brattstrom D, Bergqvist M, Lamberg K, et al. Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med Oncol 1998; 15: 255-61.
36. Brooks KR, To K, Moore JMB, et al. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Ann Thorac Surg 2003; 76: 187-93.
37. Fisher JR, Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 2004; 45 (suppl 2): 151-61.
38. King TC, Akerley W, Fan AC, et al. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 2000; 89: 769-73.
39. Safran H, King T, Choy H, et al. p53 mutations do not predict response to paclitaxel/radiation for nonsmall cell lung carcinoma. Cancer 1996; 78: 1203-10.
40. Gion M. Prognostic and predictive molecular markers: are we ready for their clinical use? The opinion of a clinical biochemist. Int J Biol Markers 2003; 18: 62-4.
41. Korobowicz E, Zdunek M. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy. Pol J Pathol 2000; 51: 71-6.